Baumeister Marcus, Vogel Marc, Dürsteler-MacFarland Kenneth M, Gerhard Urs, Strasser Johannes, Walter Marc, Wiesbeck Gerhard A, Petitjean Sylvie A
Outpatient Addiction Treatment Center Reinach, Psychiatry Baselland, Baselstrasse 1, 4153 Reinach, Switzerland.
Subst Abuse Treat Prev Policy. 2014 Dec 4;9:46. doi: 10.1186/1747-597X-9-46.
Concomitant cocaine use is a major problem in clinical practice in methadone maintenance treatment (MMT) and may interfere with successful treatment. Data from European methadone populations is sparse. This register-based study sought to explore the association between prescribed methadone dose and concomitant cocaine and heroin use in the methadone population of Basel City.
The study included 613 methadone patients between April 1, 2003 and March 31, 2004. Anonymized data was taken from the methadone register of Basel City. For analysis of the prescribed methadone dose distribution, the patient sample was split into three methadone dosage groups: a low dose group (LDG) (n = 200; < 60 mg/day), a medium dose group (MDG) (n = 273; 60 to 100 mg/day), and a high dose group (HDG) (n = 140; > 100 mg/day). Concomitant drug use was based on self-report.
Analysis showed a significant difference in self-reported cocaine use between groups (p < 0.001). Patients in the LDG reported significantly fewer cocaine consumption days compared to the MDG (p < 0.001) and the HDG (p < 0.05). Patients in the HDG reported significantly fewer heroin consumption days than those in the LDG (p < 0.01) and the MDG (p < 0.001). In logistic regression analysis, cocaine use was significantly associated with heroin use (OR 4.9).
Cocaine use in methadone patients may be associated with heroin use, which indicates the importance of prescribing appropriate methadone dosages in order to indirectly reduce cocaine use.
在美沙酮维持治疗(MMT)的临床实践中,同时使用可卡因是一个主要问题,可能会干扰治疗的成功。来自欧洲美沙酮人群的数据稀少。这项基于登记册的研究旨在探讨巴塞尔市美沙酮人群中规定的美沙酮剂量与同时使用可卡因和海洛因之间的关联。
该研究纳入了2003年4月1日至2004年3月31日期间的613名美沙酮患者。匿名数据取自巴塞尔市的美沙酮登记册。为了分析规定的美沙酮剂量分布,将患者样本分为三个美沙酮剂量组:低剂量组(LDG)(n = 200;<60毫克/天)、中剂量组(MDG)(n = 273;60至100毫克/天)和高剂量组(HDG)(n = 140;>100毫克/天)。同时使用药物基于自我报告。
分析显示各组之间自我报告的可卡因使用情况存在显著差异(p < 0.001)。与MDG(p < 0.001)和HDG(p < 0.05)相比,LDG中的患者报告的可卡因消费天数显著减少。HDG中的患者报告的海洛因消费天数比LDG(p < 0.01)和MDG(p < 0.001)中的患者显著减少。在逻辑回归分析中,可卡因使用与海洛因使用显著相关(OR 4.9)。
美沙酮患者使用可卡因可能与使用海洛因有关,这表明开具适当美沙酮剂量以间接减少可卡因使用的重要性。